Aquinox Pharmaceuticals Receives Regulatory Clearance to Initiate First Clinical Study of AQX-1125, A Novel Oral Anti-Inflammatory Compound Vancouver, British Columbia - January 5, 2011 Aquinox Pharmaceuticals Inc., a private, venture-backed, biopharmaceutical company developing novel and targeted
Aquinox Pharmaceuticals Selects AQX-1125 as Lead Clinical Candidate Vancouver, Canada and London, UK - October 11, 2009 Aquinox Pharmaceuticals Inc., a private, venture-backed, biopharmaceutical company developing novel and targeted small molecule therapeutics for the treatment of inflammatory
Aquinox Pharmaceuticals Inc. Names Board Member Vancouver, British Columbia - July 10, 2008 Aquinox Pharmaceuticals is pleased to announce the addition of Dr. Daniel Levitt as an independent member of the Board of Directors. Dr. Levitt joined Cerimon Pharmaceuticals Inc.
With help from Mother Nature: A Novel New Drug Discovery May Revolutionize Treatment of Inflammatory Diseases and Leukemia September 14, 2007 If you found yourself on a run-away train, would you want to switch on the brakes? Two Vancouver Coastal Health Research Institute (VCHRI) and University of
